Projects per year
- Improving the understanding and management of co-morbidity and co-infection in people living with HIV
- Epidemiology of HIV in the Netherlands
Since the inception of the AGEhIV cohort study in 2009 I have together with the study PI prof. P. Reiss (Professor of Internal Medicine, in particular the complications of HIV treatment), acted as a senior clinical co-investigator of the study contributing to the design and excecution of a range of studies performed by successive PhD students on the study. (www.agehiv.nl)
As of 2016 I acted as the principal investigator of the MC Free study which aims to eliminate hepatitis C infections in hiv-positive men who have sex with men. This study nicely complements the HIV transmission elimination Amsterdam (www.hteam.nl) aiming to reduce new HIV infections in Amsterdam. As of 2017 I am a member of H team's executive committee. Both MC Free and H-team are prominent examples of implementation research projects.
As of 2020 I am leading a project to develop a national toolkit for peer-to-peer support in HIV care and initiated a PROMS-based program to improve the quality of care of people living with HIV at the Amsterdam UMC and DC clinics HIV-outpatient clinic.
From 2021 I am director of the Board of Stichting hiv monitoring (SHM) foundation (ATHENA),an insititute that collects data on people living with HIV in the Netherlands. Apart from being responsible for SHMs yearly monitoring report, which can be found at Home | Stichting HIV Monitoring (hiv-monitoring.nl) as a PI of the ATHENA cohort I collaborate with multiple international partners in large international consortia.
Expertise related to UN Sustainable Development Goals
In 2015, UN member states agreed to 17 global Sustainable Development Goals (SDGs) to end poverty, protect the planet and ensure prosperity for all. This person’s work contributes towards the following SDG(s):
PhD, Metabolic complications of antiretroviral therapy in HIV
1999 → 2003
Award Date: 5 Sep 2003
director of the board, Stichting HIV Monitoring, Amsterdam, the Netherlands.
2021 → …
member EACS HIV treatment guideline committee
2021 → …
board member Amsterdam Diner Foundation
2018 → …
member H team (www.hteam.nl) executive committee
1 Jan 2017 → …
chairman of the board of the HIV monitoring foundation, Stichting HIV Monitoring, Amsterdam, the Netherlands.
2017 → 2021
board member HEPNED
2017 → …
member conference coordinating committee AIDS 2018 Amsterdam
2016 → 2018
chairman Dutch Society of HIV treating physicians
1 Jan 2014 → 2020
Member Dutch HIV treatment guideline committee
2014 → 2020
Member Dutch HCV treatment guideline committee
2014 → …
Member Dutch HBV treatment guideline committee
2014 → …
Dive into details
Select a country/territory to view shared publications and projects
- 1 Active
Reiss P.: Complications of HIV and HIV treatment
van den Hof, M., Kooij, K. W., Langebeek, N., Schouten, J., Su, T., Verboeket, S. O., Verheij, E., van Zoest, R. A., Reiss, P., Kootstra, N. A., van der Valk, M. & Wit, F. W. N. M.
1/11/2006 → …
Liver fibrosis in HIV-infected individuals on long-term antiretroviral therapy: associated with immune activation, immunodeficiency and prior use of didanosineKooij, K. W., Wit, F. W. N. M., van Zoest, R. A., Schouten, J., Kootstra, N. A., van Vugt, M., Prins, M., Reiss, P. & van der Valk, M., 2016, In: AIDS (London, England). 30, 11, p. 1771-1780
Research output: Contribution to journal › Article › Academic › peer-review29 Citations (Scopus)
Sofosbuvir shows antiviral activity in a patient with chronic hepatitis E virus infectionvan der Valk, M., Zaaijer, H. L., Kater, A. P. & Schinkel, J., 2017, In: Journal of hepatology. 66, 1, p. 242-243
Research output: Contribution to journal › Comment/Letter to the editor › Academic55 Citations (Scopus)
Sofosbuvir plus simeprevir for the treatment of HCV genotype 4 patients with advanced fibrosis or compensated cirrhosis is highly efficacious in real lifeWillemse, S. B., Baak, L. C., Kuiken, S. D., van der Sluys Veer, A., Lettinga, K. D., van der Meer, J. T. M., Depla, A. C. T. M., Tuynman, H., van Nieuwkerk, C. M. J., Schinkel, C. J., Kwa, D., Reesink, H. W. & van der Valk, M., Dec 2016, In: Journal of viral hepatitis. 23, 12, p. 950-954 5 p.
Research output: Contribution to journal › Article › Academic › peer-review22 Citations (Scopus)
Cost-effectiveness analysis of pre-exposure prophylaxis for HIV-1 prevention in the Netherlands: a mathematical modelling studyNichols, B. E., Boucher, C. A. B., van der Valk, M., Rijnders, B. J. A. & van de Vijver, D. A. M. C., 2016, In: Lancet infectious diseases. 16, 12, p. 1423-1429
Research output: Contribution to journal › Article › Academic › peer-review75 Citations (Scopus)
Cross-sectional comparison of the prevalence of age-associated comorbidities and their risk factors between HIV-infected and uninfected individuals: the AGEhIV cohort studyAUTHOR GROUP, 2014, In: Clinical Infectious Diseases. 59, 12, p. 1787-1797
Research output: Contribution to journal › Article › Academic › peer-review514 Citations (Scopus)